|Dr. Weiss has authored over 350 published, peer-reviewed medical articles, chapters and abstracts. Among his research accomplishments (as lead or senior author, except as noted):
? First assessment of the prototype HIV screening test.
? Part of the team describing the 2nd case worldwide of HTLV-II infection.
? First demonstration of high infection rates with HTLV-II in drug users.
? First report that among persons seropositive for HIV antibody, adverse outcomes had significant latency, and these steadily mounted over time to high rates of severe disease and death.
? First demonstrated US case (2nd worldwide) of occupational acquisition of HIV in healthcare workers, associated this with HIV needlestick) exposure, and leading to vast changes in the workplace.
? First case of occupational acquisition of HIV in research workers.
? First US case of HIV-2 ? detected at University Hospital, Newark.
? First demonstration of female to male sexual transmission of HIV.
? Part of the team documenting the 2nd case of female to female HIV transmission.
? First demonstration that the latency from initial asbestos exposure until development of mesothelioma is longer than was typically appreciated.
? First to demonstrate that the US epicenter for HIV infection in injection drug users centered about NYC and Jersey City, NJ, and the first to enroll women in an HIV-era cohort study.
? First to assess geographic distribution of asthma in children across an entire state.
-CONTINUED || |
|? First to discover confirmed very high rates of the hepatitis C virus (HCV) in drug users, presaging the epidemic consequences of HCV (liver failure and hepatocellular carcinoma).
? A member of the team demonstrating immunologic abnormalities associated with HTLV-II, such as spontaneous lymphocyte proliferation and lymphocyte subset changes, and advisor to the FDA about HTLV-II and blood product screening
|Wilson RT, Hasanali SH, Sheikh M, Cramer S, Weinberg G, Firth A, Weiss SH, Soskolne CL. Challenges to the Census: International Trends and a Need to Consider Public Health Benefits. Public Health. 151 October: 87-97, 2017. Accepted 21 May 2017. Online July 2017: https://doi.org/10.1016/j.puhe.2017.05.015|| |
|Weiss SH, Goedert JJ, Sarngadharan MG, The AIDS Seroepidemiology Collaborative Working Group, Gallo RC, Blattner WA. Screening test for HTLV-III (AIDS agent) antibodies: specificity, sensitivity and applications. The Journal of the American Medical Association 253:221-225, 1985.
Also published in: JAMA Edition Francaise 99:445-453, 1985; JAMA Deutsche Ausgabe 5: 310- 317; JAMA Southeast Asia Edition 1: 23-27, 1985; JAMA Belgische Uitgave 4:35-39, 1985; and JAMA Japanese Edition 253:29-35, 1985.
This was one of the 100 most-cited 1985 life-sciences articles [cf.: The Most-Cited 1985 Life-Sciences Articles in Essays of an Information Scientist, Vol:10, pp.293-302, 1987 Current Contents, #41, p.3, October 12, 1987].
Reprinted by JAMA The Journal of the American Medical Association 07/2014; 312(4):442. doi:10.1001/jama.2013.279636 ? 30.39 Impact Factor
|Landesman SH, Ginzburg HM, Weiss SH. Special report: The AIDS epidemic. The New England Journal of Medicine 312:521-525, 1985. doi:10.1056/NEJM198502213120828.
54.42 Impact Factor
|Weiss SH, Saxinger WC, Rechtman D, Grieco MH, Nadler J. Holman S, Ginzburg HM, Groopman JE, Goedert JJ, Markham PD, Gallo RC, Blattner WA, Landesman SH. HTLV-III infection among health care workers: association with needle-stick injuries. The Journal of the American Medical Association 254:2089-2093, 1985. doi:10.1001/jama.1985.03360150065025. 30.39 Impact Factor
Also published in: JAMA Edition Francaise 10: 164-172, 1986; and JAMA Deutsche Ausgabe 5:342-349, 1986. Abstracted in Infectious Diseases Digest 6:24-25, 1986; and in 1987 Year Book of Anesthesia. Reprinted by U.S. Occupational Safety and Health Administration in their Infectious Diseases Training Manual
|Weiss SH, Mann DL, Murray C, Popovic M. HLA-DR antibodies and HTLV-III antibody ELISA testing. Lancet 2:157, 1985. doi:10.1016/S0140-6736(85)90261-2.
45.22 Impact Factor|| |
|Goedert JJ, Biggar RJ, Weiss SH, Eyster ME, Melbye M, Wilson S, Ginzburg HM, Grossman RJ, DiGioia RA, Sanchez WC, Giron J, Ebbesen P, Gallo RC, Blattner WA. Three-year incidence of AIDS in five cohorts of HTLV-III infected risk group members. Science 231:992-995, 1986. doi:10.1126/science.3003917
31.48 Impact Factor|| |
|Weiss SH, Blaser MJ, Paleologo FP, Black RE, Asbury MA, Carter GP, Feldman RA, Brenner DJ. The occurrence and distribution of serotypes of the arizona subgroup of salmonella in the United States, 1967-1976. Journal of Clinical Microbiology 23:1054-1064, 1986.|| |
|Weiss SH, Goedert JJ, Gartner S, Popovic M, Waters D, Markham P, diMarzo-Veronese F, Gail MH, Barkley WE, Gibbon J, Gill FA, Leuther M, Shaw GM, Gallo RC, Blattner WA. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science 239:68-71, 1988. || |